<h1>Aptus Pharma Clarifies Typographical Errors in Outcome of Board Meeting Held on August 8, 2026</h1>
Aptus Pharma Ltd has issued a clarification regarding inadvertent typographical errors present in the submission of the Outcome of its Board of Directors meeting, which was held on Saturday, August 8, 2026.
The company addressed two key clerical mistakes found in the initial documentation concerning the meeting. Firstly, the venue for the meeting had been stated as 'the registered office of the Company,' when it should have specified 'the Head Office of the Company situated at RK Trade Tower, Wing A, Ofice Nos. 616 to 619, Near Sheetal Park Circle, 150 Feet Ring Road, Rajkot, Gujarat, India - 360006.'
To accurately reflect this correction, the reference to 'the registered office of the Company' in the opening paragraph should be read as: 'the Head Office of the Company situated at RK Trade Tower, Wing A, Ofice Nos. 616 to 619, Near Sheetal Park Circle, 150 Feet Ring Road, Rajkot, Gujarat, India - 360006.'
Additionally, a typographical correction relates to an annexure mentioned in the previous submission. The document referred to as 'Annexure A' was inadvertently titled 'Annexure 1' within the annexure itself. Consequently, the title 'Annexure 1' should be read as 'Annexure A'.
Aptus Pharma confirmed that these errors are purely typographical and stated that there is no change in the substance, decisions, or outcomes of any resolution passed or matter considered by the Board of Directors at the aforementioned meeting. The company requested that this clarification be taken on record with the corrections provided.
Stock Price Movement
As of 10:14, shares of Aptus Pharma Ltd are ticking down, currently trading at ₹274.25, marking a decline of 1.98%. The stock is completely locked at this price point, having traded flat with the high and low both set exactly at ₹274.25.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.